The Epstein-Barr virus (EBV) is a common lifelong infection, but its reactivation can lead to multiple sclerosis (MS). People with EBV are 32 times likelier to develop MS, underlining the need for a vaccine. The mRNA technology, developed for COVID-19 by Moderna and Pfizer/BioNTech, could be the key to an EBV vaccine. This technology instructs our cells to create a virus-specific protein, helping our immune system recognize the virus without requiring a live virus. Several potential EBV vaccines are currently in human trials, despite some controversy about the need for a vaccine given MS's rarity. However, an EBV vaccine could lessen the impact of EBV-associated diseases and reveal more about the virus's role in autoimmune disease. An effective vaccine could bring a world free from EBV-related diseases nearer.
Full article here: https://medium.com/@lawsuithelpdesk/researchers-are-undertaking-an-historic-effort-to-develop-a-vaccine-for-the-epstein-barr-virus-a-95671b0e5fae